← All trials
NCT06137950
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 7, 2023
- Primary completion
- Mar 15, 2024
- Completion date
- Sep 15, 2024
- First posted
- Nov 18, 2023
- Last posted
- Nov 18, 2023
- Enrollment
- 90
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mongolian National University of Medical SciencesLead sponsor
- Mongolian National University of Medical SciencesReponsible party - principal investigator
- Mongolian National University of Medical SciencesSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.